| GTO ID | GTC1003 |
| Trial ID | ChiCTR2200061435 |
| Disease | Glioblastoma |
| Altered gene | XYF13 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | XYF13 CAR-T cells |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A open-label study evaluating the safety, tolerability and preliminary efficacy of XYF13 Car-T in the patients with recurrent glioblastoma |
| Year | 2022 |
| Country | China |
| Company sponsor | Xi'an Central Hospital |
| Cohort 1 | |||||||
|
|||||||